ReCode Therapeutics to Present at William Blair Biotech Focus Conference 2021
MENLO PARK, Calif. & DALLAS--(BUSINESS WIRE)-- ReCode Therapeutics (the “Company”), a biopharmaceutical company pioneering disease-modifying genetic medicines using its SORT-LNPTM platform, today announced that CEO and President, David Lockhart, Ph.D., will participate in a panel discussion on non-viral drug delivery at the upcoming William Blair Biotech Focus Conference 2021 at 2:00 pm Eastern Time on Thursday, July 15, 2021.
An archived replay of the presentation will be made available on the Company’s website following the presentation.
About ReCode Therapeutics
ReCode Therapeutics is an integrated genetic medicines company developing disease-modifying therapeutics using its powerful, proprietary SORT-LNPTM platform to target organs and tissues beyond the liver. The Company’s pipeline includes lead programs for patients with life-limiting genetic respiratory diseases, including cystic fibrosis and primary ciliary dyskinesia. The Company is leveraging its SORT-LNPTM and nucleic acid technologies and utilizing systemic and direct delivery for mRNA-mediated replacement and gene editing/correction in target cells, including stem cells. For more information, visit www.recodetx.com and follow us on Twitter @ReCodeTx and LinkedIn.
Source: ReCode Therapeutics